Theravance Biopharma (TBPH) Misses Q1 EPS by 13c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.27), $0.13 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $5.58 million.

Cash, cash equivalents, and marketable securities totaled $540.7 million as of March 31, 2017.

2017 Financial Guidance

The Company's guidance on operating loss excluding non-cash share-based compensation for the full-year of 2017 remains unchanged at $195.0 million to $205.0 million. The actual amount could be above or below this forecast as a result of a variety of factors impacting our business, including business development transactions, the timing and cost of clinical and non-clinical studies associated with our key programs, and net product sales of VIBATIV.

Rick E Winningham, Chairman and Chief Executive Officer, commented: "As we progress into mid-2017, we are on track to deliver clinical results at every stage of development through the remainder of this year and into 2018. This unprecedented period for the Company underscores the depth and breadth of our portfolio, the productivity of our internal R&D engine, and our robust business model. In addition, the Closed Triple for COPD represents an important strategic asset and a promising potential source of income for Theravance Biopharma in both the near and long-term. With a strong cash position and an extensive set of milestones ahead of us, we believe we are well-positioned to improve the lives of patients and create meaningful value for our shareholders."

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Netskope, Inc. (NTSK) Tops Q1 EPS by 1c, Offers Guidance
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance